Mazdutide
Mazdutide is a weekly GLP-1 and glucagon receptor injection developed by Innovent Biologics under a license from Eli Lilly. China approved it for weight management in 2025. It is not approved in the U.S.
Mazdutide (formerly IBI362, LY3305677)
Also searched as: IBI362, LY3305677.
Educational information. This page does not give dosing instructions or tell you what to take. Ask a prescriber about your own care.
In plain English
Mazdutide (also called IBI362 and LY3305677) is a once-weekly injection that activates the GLP-1 receptor and the glucagon receptor. Eli Lilly discovered it. Innovent Biologics licensed it for China and ran the large trials there.
In GLORY-1, Chinese adults with overweight or obesity lost an average of 11.0% (4 mg) or 14.0% (6 mg) of body weight after 48 weeks, while placebo was about unchanged. In GLORY-2, a higher 9 mg amount led to an average loss of 16.65% at 60 weeks versus 1.5% on placebo.
According to the company, China's drug regulator approved mazdutide for long-term weight management in adults with overweight or obesity in June 2025. It is not FDA approved. All the large trials so far were done in China, in people who weigh less on average than people in most U.S. trials, so the percentages are not a like-for-like match.
Brand names and products
A generic name identifies the drug itself. A brand name identifies one company's product. One drug can come in several products with different forms and approved uses, so the brand name often tells you more about what a prescription is for.
No brand name is recorded for this medicine because there is no approved product.
Approved and investigational. In the U.S., every use of mazdutide is investigational. It is approved only in China.
How it works
Mazdutide is a peptide that activates the GLP-1 receptor, which lowers appetite, and the glucagon receptor, which is thought to add to weight loss. It is designed to be given once a week.
Forms and approval status
| Form | How it is taken | U.S. status |
|---|---|---|
| Mazdutide injection (approved in China, investigational in the U.S.) | Once weekly in trials. Not available in the U.S. outside clinical trials. | Not approved by the FDA. According to the company, China's regulator (NMPA) approved it for chronic weight management in adults in June 2025, and an application for type 2 diabetes in China was reported to be under review at that time. Approval status in other countries was not found. |
What the trials found
These are group averages from published trials in adults without diabetes unless stated. See how to read trial numbers before comparing.
GLORY-1
Average change in body weight. Every bar uses one scale, 0 to 25 percent.
- People studied
- 610 adults in China, aged 18 to 75, with a BMI of 28 or more, or 24 to under 28 plus a weight-related condition
- Length
- 48 weeks
- Compared with
- Placebo. Mazdutide 4 mg or 6 mg once weekly. The main comparison was set at week 32, with follow-up to week 48
- What was measured
- Average change in body weight at week 48
- Analysis approach
- Treatment-policy estimand (stated for the week 32 main analysis): effects regardless of early stopping or new weight-loss therapy
- Other results
- At week 32 the average change was -10.09% (4 mg) and -12.55% (6 mg) vs +0.45% with placebo. At week 48, weight loss of at least 15% occurred in 35.7% (4 mg) and 49.5% (6 mg) vs 2.0% with placebo.
- Safety
- Stomach and gut side effects were the most common and mostly mild to moderate. Side effects led to stopping in 1.5% (4 mg), 0.5% (6 mg) and 1.0% (placebo) of participants.
- Limits
- Conducted only in China, in people with a lower average starting weight (87 kg) than in most Western trials, so percentage figures are not directly comparable with them. Funded by the manufacturer. Group averages do not predict one person's result.
Sources: Ji L 2025
GLORY-2
Average change in body weight. Every bar uses one scale, 0 to 25 percent.
- People studied
- 461 treated adults in China with a BMI of 30 or more (16.1% also had type 2 diabetes)
- Length
- 60 weeks
- Compared with
- Placebo, with a reduced-calorie diet and more physical activity in both groups. Mazdutide 9 mg once weekly
- What was measured
- Average change in body weight at week 60
- Analysis approach
- The published abstract does not name the estimand
- Other results
- Weight loss of at least 5%: 84.3% with mazdutide vs 33.1% with placebo.
- Safety
- Vomiting (53.1% vs 1.3%), nausea (46.9% vs 3.2%) and diarrhea (39.4% vs 6.5%) were the most common side effects, mostly mild to moderate. Side effects led to stopping in 2.9% on mazdutide and 0% on placebo.
- Limits
- Conducted only in China, in a fairly young group (average age 33.9). Sponsored by the manufacturer. The 9 mg amount is higher than the amounts used in GLORY-1. Group averages do not predict one person's result.
Sources: Gao L 2026, GLORY-2 trial record (NCT06164873)
Safety
No FDA label exists for this medicine yet. The information below comes from published trial reports. The points below are a summary and may be incomplete.
Boxed warning and label notes
- Mazdutide injection (approved in China, investigational in the U.S.): Not applicable in the U.S. No FDA label exists.
Warnings labels describe
- No FDA label exists. Safety information here comes from trial reports.
- Because it activates the GLP-1 receptor, the safety points seen with that class are expected to be relevant. The Chinese label was not read for this atlas.
Most common in trials
- Nausea
- Vomiting
- Diarrhea
- Other stomach and gut side effects, mostly mild to moderate
Less common but serious
- The published abstracts report that most side effects were mild to moderate. At 9 mg, side effects led to stopping in 2.9% of people on mazdutide. Details on serious events are in the full papers.
What is still unknown
- Whether it will be filed with the FDA or approved outside China. Lilly's plans for it were not found.
- How it performs in larger, more diverse trials outside China.
- The exact dose and label wording approved in China. The company announcement did not state them.
- How it compares with tirzepatide or semaglutide in a head-to-head trial.
- Long-term safety and weight regain after stopping.
Compiled from public information: FDA-approved labels, manufacturer websites, ClinicalTrials.gov and published journal articles. Sources are listed at the bottom of this page.
Sources
- Innovent announces mazdutide, the first dual GCG/GLP-1 receptor agonist, received approval from China's NMPA for chronic weight management Innovent Biologics press release, June 27, 2025, via BioSpace. Company announcement; not peer reviewed. Trade press, secondary source
- Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1) Ji L, et al. N Engl J Med. 2025;392(22):2215-2225. PMID 40421736. Funding: Innovent Biologics. Journal article
- Treatment with 9-mg mazdutide for weight reduction in Chinese adults with obesity: the GLORY-2 randomized clinical trial Gao L, et al. JAMA. 2026;336(5):377-388. PMID 42251595. Funding: Innovent Biologics (trial sponsor). Journal article
- GLORY-2 trial record (NCT06164873) ClinicalTrials.gov identifier NCT06164873. Sponsor: Innovent Biologics. Trial registry
- ClinicalTrials.gov U.S. National Library of Medicine. Trial registry